glp-1 receptor agonists and sglt2 inhibitors Complementary Yet Distinct Roles of in Cardiovascular Risk Reduction Complementary Yet Distinct Roles of

The success of these agents in preclinical models and clinical trials suggests a promising future for multiagonists in the treatment of metabolic diseases, with the most recent glucose-dependent insulinotropic peptide receptor:glucagon-like peptide 1 receptor:glucagon receptor (GIPR:GLP-1R:GCGR) triagonists rivaling the efficacy of bariatric surgery

Leave-one-out sensitivity analyses confirmed the direction and magnitude of the AUD finding but highlighted the limited evidence base for hospitalization

Liv Wellness RX

Therefore, further research is necessary to fully understand the potential of GLP-1 receptor agonists in providing comprehensive protection against complications related to T2DM.

Regulatory submission for retatrutide is expected in 2026